Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Biochemical Pharmacology

• Publication date

  2014-05-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bcp.2014.02.012PMID 24565910PMCID PMC3983711
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting the ABCG2‐overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists

  2013cited by this paper
• The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.

  2013cited by this paper
• Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models.

  2013cited by this paper
• Bureau of Disease Prevention and Control, Ministry of Health, Beijing 100044, P. R. China

  2013cited by this paper
• Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.

  2012cited by this paper
• Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells.

  2012cited by this paper
• Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

  2012cited by this paper
• GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance.

  2012cited by this paper
• Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?

  2011cited by this paper
• Novel Acrylonitrile Derivatives, YHO-13177 and YHO-13351, Reverse BCRP/ABCG2-Mediated Drug Resistance In Vitro and In Vivo

  2011cited by this paper
• The challenge of exploiting ABCG2 in the clinic.

  2011cited by this paper
• Revisiting the ABCs of multidrug resistance in cancer chemotherapy.

  2011cited by this paper
• Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer

  2011cited by this paper
• The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone.

  2010cited by this paper
• Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding

  2009cited by this paper
• Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties

  2009cited by this paper
• PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.

  2009cited by this paper
• Transporters as drug carriers : structure, function, substrates

  2009cited by this paper
• Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.

  2009cited by this paper
• Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

  2009influential reference
• Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

  2008cited by this paper
• Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

  2008cited by this paper
• Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.

  2008cited by this paper
• Homology modeling of breast cancer resistance protein (ABCG2).

  2008cited by this paper
• The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox).

  2008cited by this paper
• Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 (Cancer Research (2008) 68, (7905-7914))

  2008cited by this paper
• Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.

  2007cited by this paper
• ABCG2: determining its relevance in clinical drug resistance

  2007cited by this paper
• Chemotherapy-induced resistance by ATP-binding cassette transporter genes.

  2007cited by this paper
• Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.

  2006cited by this paper
• Drug resistance in brain diseases and the role of drug efflux transporters

  2005cited by this paper
• Tumour stem cells and drug resistance

  2005cited by this paper
• Mutations

  2004cited by this paper
• A distinct "side population" of cells with high drug efflux capacity in human tumor cells.

  2004cited by this paper
• ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan‐treated metastases

  2004cited by this paper
• Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing binding.

  2004cited by this paper
• Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients.

  2004cited by this paper
• Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.

  2003cited by this paper
• Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants

  2003cited by this paper
• ABCG2 (BCRP) expression in normal and malignant hematopoietic cells

  2003cited by this paper
• A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport.

  2003cited by this paper
• Frequent expression of the multi‐drug resistance‐associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP‐21 monoclonal antibody in paraffin‐embedded material

  2002cited by this paper
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002cited by this paper
• Mechanisms of cancer drug resistance.

  2002cited by this paper
• Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)

  2002cited by this paper
• BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia

  2002cited by this paper
• The human ATP-binding cassette (ABC) transporter superfamily.

  2001cited by this paper
• Stem cells, cancer, and cancer stem cells

  2001cited by this paper
• The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

  2001cited by this paper
• Overview: ABC Transporters and Human Disease

  2001cited by this paper
• Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C.

  1998cited by this paper
• Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase.

  1992cited by this paper
• THE CALCULATION OF THE DOSAGE-MORTALITY CURVE

  1935cited by this paper

• Repurposing the Tyrosine Kinase Inhibitors Targeting FGFR and VEGFR Pathways for Cancer Therapy: A Comprehensive Review

  2025cites this paper
• ATP-Binding Cassette Subfamily G Member 2 in Acute Myeloid Leukemia: A New Molecular Target?

  2024cites this paper
• RN486, a Bruton's Tyrosine Kinase inhibitor, antagonizes multidrug resistance in ABCG2-overexpressing cancer cells

  2024cites this paper
• Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: in vitro and in vivo studies.

  2024cites this paper
• To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors.

  2023cites this paper
• Drug resistance of hepatoma cells induced by ATP‑binding cassette transporter G2 by reducing intracellular drug concentration.

  2023cites this paper
• VKNG-1 Antagonizes ABCG2-Mediated Multidrug Resistance via p-AKT and Bcl-2 Pathway in Colon Cancer: In Vitro and In Vivo Study

  2021influential citation
• Cabozantinib Reverses Topotecan Resistance in Human Non-Small Cell Lung Cancer NCI-H460/TPT10 Cell Line and Tumor Xenograft Model

  2021cites this paper
• The Novel benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter

  2021cites this paper
• UPDATE ON DRUG TRANSPORTER PROTEINS IN ACUTE MYELOID LEUKEMIA: PATHOLOGICAL IMPLICATION AND CLINICAL SETTING.

  2021cites this paper
• Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles

  2021cites this paper
• Application of Immunohistochemistry in Basic and Clinical Studies.

  2020cites this paper
• Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration

  2020cites this paper
• Antiangiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors.

  2020cites this paper
• Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition

  2019cites this paper
• Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.

  2019cites this paper
• Optimization Of Cancer Treatment Through Overcoming Drug Resistance

  2018cites this paper
• Characterization of novel flavonoid dimers as breast cancer resistance protein (BCRP)-modulators

  2018cites this paper
• Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells

  2018cites this paper
• Mycoplasma-associated multidrug resistance of hepatocarcinoma cells requires the interaction of P37 and Annexin A2

  2017cites this paper
• The dopamine D3 receptor antagonists PG01037, NGB2904, SB277011A, and U99194 reverse ABCG2 transporter-mediated drug resistance in cancer cell lines.

  2017cites this paper
• Pharmacokinetic interactions in mice between irinotecan and MBL‐II‐141, an ABCG2 inhibitor

  2017cites this paper
• ABCG2/BCRP: Specific and Nonspecific Modulators

  2017cites this paper
• ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics

  2017cites this paper
• Mechanistic and Pharmacological Insights into Modulation of ABC Drug Transporters by Tyrosine Kinase Inhibitors

  2016cites this paper
• ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer

  2016influential citation
• Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer

  2016cites this paper
• Product Data Sheet Chemical Properties Product

  2016cites this paper
• Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade.

  2016cites this paper
• Gibberellin derivative GA-13315 sensitizes multidrug-resistant cancer cells by antagonizing ABCB1 while agonizes ABCC1

  2016cites this paper
• New Hopes in Cancer Battle - A Review of New Molecules and Treatment Strategies.

  2016cites this paper
• Dielectrophoretic Microfluidic Chip Enables Single-Cell Measurements for Multidrug Resistance in Heterogeneous Acute Myeloid Leukemia Patient Samples.

  2016cites this paper
• Reversal of Multidrug Resistance Fluorescently Measured in Single Cancer Cells Captured in the Microfluidic Chip

  2015cites this paper
• Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance

  2015cites this paper
• Butorphanol, a synthetic opioid, sensitizes ABCB1-mediated multidrug resistance via inhibition of the efflux function of ABCB1 in leukemia cells.

  2015cites this paper
• Esters of the Marine-Derived Triterpene Sipholenol A Reverse P-GP-Mediated Drug Resistance

  2015cites this paper
• Isolation and characterization of side population cells from the human ovarian cancer cell line SK-OV-3

  2015cites this paper
• Resistance to Targeted ABC Transporters in Cancer

  2015cites this paper
• The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade.

  2015cites this paper
• A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo

  2015cites this paper
• The Role of ABC Multidrug Transporters in Resistance to Targeted Anticancer Kinase Inhibitors

  2015cites this paper
• SLC transporters as therapeutic targets: emerging opportunities

  2015cites this paper
• ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy.

  2015cites this paper
• Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2

  2014cites this paper
• Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.

  2014cites this paper
• AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.

  2014cites this paper
• Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance

  2014cites this paper
• CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function.

  2014cites this paper
• The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study

  2014cites this paper
• MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts

  2014influential citation
• Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance

  2014influential citation